DNA Vaccines 2010 in New Orleans was a great success. Watch this site for updated info for dates and location of the next DNA Vaccines conference.
Hosted by Mary Ann Liebert, organized by BioConferences and Program Chair Dr. David B. Weiner, PhD. – University of Pennsylvania, USA
March 2 - 4, 2010
Sheraton New Orleans Hotel
New Orleans, LA
Final Agenda:
MARCH 2, 2010
Registration Opens: 9am - 5pm
Morning Sessions
Session Chair: John Shiver, Connie Schmaljohn
10:00 — 10:30AM
Welcome Address from the Program Chairman: Enhancing DNA Vaccine Immunity in Vivo
David B. Weiner, PhD — University of Pennsylvania
10:30 — 11:00AM
The Future of Vaccines from an Industry Perspective
John Shiver, PhD — Merck
11:00 — 11:30AM
Human Immune Responses to Vaccination
Mark Slifka, PhD — OSHU
11:30 — 12:00AM
Preclinical and Clinical Studies of DNA Vaccines for Biodefense
Connie Schmaljohn, PhD — USAMRIID
12:00 — 1:10PM Lunch Opens
Afternoon Session 1
Session Chairs: Iacob Matheson, Shan Lu
1:10 — 1:30PM
Live Attenuated Influenza Vaccine for Seasonal and Pandemic Applications
Hong Jin — Medimmune
1:30 — 1:50PM
The Strengths and Weaknesses of Inducing Mismatched Immunity to Expand Cross-Protection Against Influenza Viruses
Gary Kobinger, PhD — PHAC
1:50 — 2:10PM
Approaches to Influenza
Jukka Hartikka, PhD — Vical
2:10 — 2:30PM
SynCon™ DNA Vaccines for Infectious Diseases
NiranJan Sardesai, PhD — Inovio Biomedical Corporation
2:30 — 3:00PM
Approaches to HCV DNA Vaccines
Matti Sällberg, PhD — Tripep Pharma
3:00 — 3:30PM Break
Afternoon Session 2
Session Chairs: T.C. Wu, Gary Kobinger
3:30 — 3:50PM
Immunogenicity of VRC DNA Vaccines for HIV, WNV and Influenza
Julie Ledgerwood — VRC
3:50 — 4:10PM
T Cell Responses in Prostate Cancer Patients Immunized with Xenogeneic and Syngeneic PSMA DNA Vaccines
Polly Gregor, PhD — MSKCC
4:10 — 4:30PM
Therapeutic HPV DNA Vaccine Development
T.C. Wu, MD, PhD — The Johns Hopkins Medical Institutions
4:30 — 4:45PM
The PEDVAC Trial: Preliminary Safety Data from the First Therapeutic DNA Vaccination in HIV-Infected Children
Britta Wahren, MD, PhD — Karolinska Institute
4:45 — 5:00PM
Immunization with Drug-Resistant HIV-1 Enzyme Genes
Maria Isaguliants — Karolinska Institute
5:00 — 7:30PM Cocktail Social Hour in Exhibits Poster Area
MARCH 3, 2010
8:00 — 9:00AM Breakfast
Morning Session 1
Session Chairs: Mark Bagarazzi, Jeffrey Ulmer
9:00 — 9:30AM
RV 144 ALVAC-HIV/AIDSVAX Study: Implications for HIV Vaccine Development
Col. Nelson Michael, MD, PhD — Walter Reed Army Institute of Research, US Military HIV Research Program (MHRP)
9:30 — 10:00AM
Technologies for Improved Vaccines
Jeffrey Ulmer, PhD — Novartis Vaccines & Diagnostics
10:00 — 10:30AM
Mucosal Immunology of SIV Infection
Ron Veazey, DVM, PhD — Tulane University
10:30 — 11:00AM Break
Morning Session 2
Session Chairs: Jim Mullins, Harriet Robinson
11:00 — 11:20AM
What is a Protective T Cell Response
Michael Betts, PhD — University of Pennsylvania School of Medicine
11:20 — 11:40AM
Heterologous Prime-Boost HIV Vaccines
Shan Lu, MD, PhD — University of Massachusetts Medical School
11:40 — 12:00PM
Studies in Preclinical Macaque Models of DNA/MVA Vaccines
Harriet L. Robinson, PhD — Geovax Inc.
12:00 — 1:10PM Lunch Break
Afternoon Session 1
Session Chairs: George Pavlakis, Susan Zolla-Pazner
1:10 — 1:30PM
Clinical Experiences of HIV Genetic Vaccines
Britta Wahren, MD, PhD — Karolinska Institute
1:30 — 1:50PM
Optimization of DNA and Combination Vaccines in Macaques
George Pavlakis, MD, PhD — NCI
1:50 — 2:10PM
Induction of Cross-clade Neutralizing Antibodies with a Prime/Boost Vaccine Strategy Focused on a Neutralizing Epitope
Susan Zolla-Pazner, PhD — NYU Medical School
2:10 — 2:30PM
In Vivo Electroporation Enhances the Immunogenicity of ADVAX, a DNA-based HIV-1 Vaccine Candidate, in Healthy Volunteers
Sandhya Vasan, MD — Aaron Diamond AIDS Research Center
2:30 — 2:50PM
Genomic Signatures of DNA Vaccines
Jean Boyer, PhD — University of Pennsylvania
2:50 — 3:10PM Break
Afternoon Session 2
Session Chairs: Michael Betts, Matti Sallberg
3:10 — 3:30PM
Conserved Elements Vaccine for HIV-1 Gagp24 is Immunogenic in Mice and Macaques
James Mullins, PhD — University of Washington
3:30 — 3:45PM
Co-Delivery of Mucosal Chemokine Plasmids in a Systemically Administered DNA Vaccine Elicits Systemic and Mucosal Immune Reponses in Rhesus Macaques
Michele Kutzler — Drexel University
3:45 — 4:00PM
In Vivo Intracellular Injection Needle (IvIn) Technology: A New Needle for Improved Cellular Uptake of DNA in a Live Animal
Lars Frelin — Karolinska Insitute
4:00 — 4:15PM
An Adjuvanted Therapeutic DNA Vaccine Enhances Mucosal T-Cell Responses, Reduces Virus in the Gut, and Prevents Viral Rebound in Rhesus Macaques Chronically Infected with SIV
Deborah Fuller — Albany Medical College
Industry Discussion Panel - Chair: David Weiner
4:15 — 5:00PM
Panel Discussion:
Stanley Plotkin, Joseph Kim, Andrew Murdin, Tim Leard, Jeffrey Ulmer
Dinner Speaker:
Special Invited Speaker: Correlates of Protection from Infection
Stanley Plotkin, MD — Vaxconsult LLC introduced by Andrew Murdin - Sanofi Aventis
Presentation of Maurice Hilleman Award - David Kaslow
Presentation of Richard Ginsberg Award - David Weiner
5:30 - 7:00PM Cocktail Social Hour in Exhibits Poster Area
7:00PM Gala Dinner in Banquet Hall
MARCH 4, 2010
8:00 — 9:00AM Breakfast
Morning Session 1
Session Chairs: Henry Hebel, James Williams
9:00 — 9:15AM
Developing a Successful Contact Manufacturing Organization Partnership: A Case Study
Henry Hebel — VGXi
9:15 — 9:30AM
DNA Vaccine Purification: Increasing Productivity and Purity of Plasmid DNA by Monolith Chromatography
Matjaz Peterka — BIA Separations
9:30 — 9:45AM
Improved Antibiotic-Free Plasmid Vector Design by Incorporation of Transient Expression Enhancers
James Williams — Nature Technology
9:45 — 10:00AM
Accelerating the Development and Commercialization of DNA Vaccines
Magda Marquet, PhD — Althea Technologies
10:00 — 10:20AM
Comparative Performance Evaluation of Electroporation Mediated DNA Immunization Versus Conventional Vaccine Approaches
Drew Hannaman, PhD — Ichor Medical Systems
10:20 — 10:50AM Break
Morning Session 2
Session Chairs: Bin Wang, Ruxandra Draghia-Akli
10:50 — 11:10AM
Antigen Specific Immunity after CTLA-4 Blockade: Investigating the Role of Prior Vaccination
Jianda Yuan, MD, PhD — MSKCC
11:10 — 11:30AM
Canine Melanoma Vaccine, DNA, A Review of Efficacy and Licensure
Tim Leard, DVM, PhD — Merial
11:30 — 11:50AM
Tolerogenic Vaccination to Induce Antigen Specific T Regulatory Cells to Suppress Inflammatory Responses
Bin Wang, PhD — China Agricultural University
11:50 — 12:10PM
DNA Vaccine Based on Cancer-Testis Antigen, BORIS and IL21 Molecular Adjuvant in Extremely Effective For Treatment of Metastatic Disease
Michael Agadjanyan, PhD — The Institute for Molecular Medicine
12:10 — 1:20PM Lunch
Afternoon Session
Session Chair: David Kaslow, Ashley Birkett
1:20 — 1:40PM
Recent Advances in Malaria Vaccine Development
Ashley Birkett, PhD — PATH MVI
1:40 — 2:00PM
Transformative Technologies in the Vaccine Area - How Will We Know?
David Kaslow, MD — Merck
2:00 — 2:15PM
Structure and Biological Activity of Synthetic DNA Vaccines Formulated to Nanomedicines
Julianna Lisziewicz, PhD — Genetic Immunity
2:20 — 2:35PM
Prototype Development and Pre-Clinical Immunogenicity Analysis of a Novel Minimally Invasive Electroporation Device
Kate Broderick, PhD — Inovio Biomedical Corporation
2:30 — 3:00PM Break
Vaccine Stakeholder Panel - Chair: Ray Spier
3:00 — 3:45PM
DNA Vaccines: A View from Both Sides of the Fence and Both Sides of the Pond
Panel Discussion - David Kaslow, Ruxandra Draghia-Akli, Ashley Birkett, Jeffrey Ulmer
3:45 — 4:00PM Closing Session Summary – Niranjan Sardesai, Britta Wahren & David Weiner